Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
AssigneeThe Curators of the University of Missouri
InventorsDavid E. Troutner, Wynn A. Volkert
Life of this patent
Estimating the term…
Abstract
Stable neutral-lipophilic complexes of technetium-99m (Tc-99m) useful as diagnostic radionuclidic imaging agents are formed by complexing technetium-99m pertechnetate with alkylene amine oximes (viz. propylene amine oxime) in aqueous solutions under reducing conditions. The complexes have a zero charge, contain an O--H--O ring closure bond, and are sufficiently stable for parental administration in imaging by scintillation scanning. Substituents can be attached to the C.sub.2 to C.sub.4 alkylene carbon backbone of the tetradentate amine oxime ligands to structurally modify them and produce a variety of Tc-99m-radiopharmaceuticals with specific body imaging applications.
Claims8
The class of lipophilic macrocyclic complexes of technetium-99m (Tc-99m) useful as diagnostic radionuclides, said complexes being formed by complexing in aqueous solution technetium-99m pertechnetate (TcO.sub.4.sup.- -99m) under reducing conditions with an alkylene amine oxime containing from 2 to 4 carbons in the alkylene group, said complexes having a zero charge, containing an O--H--O ring closure bond, and being sufficiently stable for parenteral administration.
The macrocyclic complex of technetium-99m (Tc-99m) useful as a diagnostic radionuclide which is formed by complexing in aqueous solution technetium-99m pertechnetate (TcO.sub.4.sup.- -99m) under reducing conditions with 2,2'-(1,3-diaminopropane) bis(2-methyl-3-butanone) dioxime (PnAO), said complex having a zero charge, containing an O--H--O ring closure bond, having a single oxygen bonded to the reduced Tc-99m, and being stable in aqueous solution when exposed to oxygen.
Dependencies are inferred from the claim text.